AT1 Receptor Gene Polymorphisms in relation to Postprandial Lipemia

Background. Recent data suggest that the renin-angiotensin system may be involved in triglyceride (TG) metabolism. We explored the effect of the common A1166C and C573T polymorphisms of the angiotensin II type 1 receptor (AT1R) gene on postprandial lipemia. Methods. Eighty-two subjects measured daytime capillary TG, and postprandial lipemia was estimated as incremental area under the TG curve. The C573T and A1166C polymorphisms of the AT1R gene were determined. Results. Postprandial lipemia was significantly higher in homozygous carriers of the 1166-C allele (9.39 ± 8.36 mM*h/L) compared to homozygous carriers of the 1166-A allele (2.02 ± 6.20 mM*h/L) (P < 0.05). Postprandial lipemia was similar for the different C573T polymorphisms. Conclusion. The 1166-C allele of the AT1R gene seems to be associated with increased postprandial lipemia. These data confirm the earlier described relationships between the renin-angiotensin axis and triglyceride metabolism

The association between erythrocyte-bound apolipoprotein B (ery-apoB) and ABO blood group phenotypes.

<p>The prevalence of the ABO blood group phenotypes per tertile are shown (A). Tertiles are based upon ery-apoB. The first tertile represents the group with the lowest ery-apoB, whereas the third tertile represents the subjects with the highest ery-apoB. The prevalence of ABO blood group phenotypes was significantly different between the three groups (P = 0.002). Ery-apoB levels were almost two-fold increased in subjects with blood group O when compared to subjects with blood group A, B or AB (P-ANOVA <0.001) (B). *P<0.05 when compared to subjects with blood group A, B or AB.</p

Characteristics of a select group of subjects with measurements of erythrocyte-bound apolipoprotein B (ery-apoB) and ABO blood group phenotype.

<p>Subjects were divided according to ABO blood group phenotype.</p>*<p>Significantly different when compared to blood group O (P<0.05).</p>**<p>Significantly different when compared to blood group A (P<0.05).</p>***<p>Significantly different when compared to blood group A, B or AB (all P<0.05).</p

Discontinuation of statin therapy did not affect erythrocyte-bound apolipoprotein B (ery-apoB).

<p>Ery-apoB was measured in subjects using statins (N = 54) at baseline and after discontinuing statin therapy for 6 weeks. Individual ery-apoB levels remained fairly stable during the 6 weeks of follow-up since ery-apoB at baseline was strongly correlated to ery-apoB after discontinuing statin therapy for 6 weeks (Spearman r: 0.828; P<0.001).</p